Nu Skin Enterprises, Inc.
NYSE:NUSHousehold & Personal Products
+$0.13 today
- Market cap
- $188.38M
- Beta
- 0.95
- P/E (TTM)
- 4.5
- EPS (TTM)
- $1.13
- Dividend yield
- 4.70%
Volume 0.59M
Average 0.57M
NUS Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Nu Skin Enterprises, Inc.NYSE: NUS
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development remains negative
Q1 FY2026 research & development was $0, compared with $0 a year earlier. Trailing-twelve-month research & development was $10.8M.
Context
- Research & development amounted to 0.0% of revenue in FY2025, down 0.8 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly research & development holds near $0 or moves back toward the trailing-twelve-month quarterly average of $2.7M.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 0 USD
- Year-over-year change
- -100.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 0 | -100.0% |
| FY2024 | 2024-12-31 | 13M | -42.5% |
| FY2023 | 2023-12-31 | 22.6M | — |
| FY2022 | 2022-12-31 | 0 | -100.0% |
| FY2021 | 2021-12-31 | 27.2M | — |
Research & Development vs competitors
How NUS compares with its peers on the latest reported figures
- NUS's LTM Mar 2026 research & development of $10.8M is the 3rd highest of the 8 companies compared; the peer median is $0.
- Its year-over-year change of -16.9% is the highest of 4, against a peer median of -36.4%.
- Research & development amounts to 0.7% of revenue for NUS, versus a peer median of 0.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $20.99M | -18.5% | -28.0% | 7.9% | |
| LTM Mar 2026 | $19.06M | -36.4% | -5.9% | 2.1% | |
| LTM Mar 2026 | $10.8M | -16.9% | — | 0.7% | |
| LTM Feb 2026 | $0 | -100.0% | +4.1% | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Apr 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding NUS) | $0 | -36.4% | -5.9% | 0.0% | |
Competitors are the stored peer set for NUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 2.7B | 2.23B | 1.97B | 1.73B | 1.49B |
| Cost of Revenue | 675.22M | 630.92M | 611.85M | 550.23M | 453.76M |
| Gross Profit | 2.02B | 1.59B | 1.36B | 1.18B | 1.03B |
| Gross Margin | 75.0% | 71.7% | 68.9% | 68.2% | 69.4% |
| Research & Development | 27.2M | 0 | 22.6M | 13M | 0 |
| Selling, General & Admin | 1.73B | 1.44B | 1.29B | 1.13B | 940.52M |
| Operating Expenses | 1.79B | 1.48B | 1.31B | 1.33B | 940.52M |
| Depreciation & Amortization | 125.02M | 72.51M | 69.22M | 69.81M | 52.26M |
| EBITDA | 368.48M | 174.97M | 202.98M | (78.83M) | 262.41M |
| EBITDA Margin | 13.7% | 7.9% | 10.3% | -4.6% | 17.7% |
| Operating Income | 233.99M | 110.85M | 48.27M | (151.59M) | 90.88M |
| Operating Margin | 8.7% | 5.0% | 2.5% | -8.8% | 6.1% |
| Interest Income | 11.16M | 10.38M | 0 | 0 | 0 |
| Interest Expense | 11M | 21.88M | 25.56M | 26.41M | 13.95M |
| Other Income / Expenses | (1.53M) | (21.88M) | (21.69M) | (23.47M) | 105.32M |
| Income Before Tax | 232.46M | 88.97M | 26.58M | (175.05M) | 196.2M |
| Pre-Tax Margin | 8.6% | 4.0% | 1.3% | -10.1% | 13.2% |
| Income Tax Expense | 85.19M | (15.81M) | 17.98M | (28.46M) | 35.99M |
| Net Income | 147.27M | 104.78M | 8.6M | (146.59M) | 160.2M |
| Net Margin | 5.5% | 4.7% | 0.4% | -8.5% | 10.8% |
| EPS (Basic) | 2.93 | 2.10 | 0.17 | (2.95) | 3.25 |
| EPS (Diluted) | 2.86 | 2.07 | 0.17 | (2.95) | 3.18 |
| Weighted Avg Shares | 50.19M | 50M | 49.71M | 49.66M | 49.29M |
| Weighted Avg Shares (Diluted) | 51.43M | 50.53M | 49.86M | 49.66M | 50.3M |
Nu Skin Enterprises, Inc.
NYSE:NUS
Intrinsic Alpha fair value
Locked
Current Price
$3.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.